UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039082
Receipt number R000044575
Scientific Title A study for skin condition by intake a food to be examined by UV irradiation. -A placebo-controlled, randomized, double-blind, cross-over trial-
Date of disclosure of the study information 2020/01/09
Last modified on 2020/06/17 09:43:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study for skin condition by intake a food to be examined by UV irradiation. -A placebo-controlled, randomized, double-blind, cross-over trial-

Acronym

A study for skin condition by intake a food to be examined by UV irradiation.

Scientific Title

A study for skin condition by intake a food to be examined by UV irradiation. -A placebo-controlled, randomized, double-blind, cross-over trial-

Scientific Title:Acronym

A study for skin condition by intake a food to be examined by UV irradiation.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Hematology and clinical oncology Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To consider the effect of taking test food capsules for 8 weeks and until the morning of the 7th day of MED irradiation after taking 8 weeks, on skin color and moisturizing after MED irradiation in comparison with control foods.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1. MED judgment by the responsible or assigned doctor.
2. Stratum corneum moisture content.
3. Skin viscoelasticity.

Key secondary outcomes

Conduct VAS on the skin every week during the intake period (9 times in total) for:
Skin viscoelasticity, Skin clarity, Youthfulness (visual impression), Improvement of rough skin, Improvement of fine wrinkles, improvement of dull skin, Improvement of laugh line.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Take 1 capsule of test food three times a day after breakfast, lunch, and dinner for 8 weeks and until the morning of the 7th day of MED irradiation after taking 8 weeks. Do not take two capsules at once if it was forgotten to take.

Interventions/Control_2

Take 1 capsule of control food three times a day after breakfast, lunch, and dinner for 8 weeks and until the morning of the 7th day of MED irradiation after taking 8 weeks. Do not take two capsules at once if it was forgotten to take.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

45 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Male and female from 30 to 45 years old with no skin disorders.
(2) Subjects with BMI of 18.5 or more and less than 30.
(3) Subjects whose skin photo type is Type I or II
(4) Subjects who can judge UV erythema on the inner skin of the upper arm.
(5) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1) Subjects who have been diagnosed with photosensitivity.
(2) Subjects taking drugs that affect skin photosensitivity.
(3) Subjects who are currently visiting a dermatologist or are being treated for other diseases.
(4) Subjects with a history of sugar metabolism, lipid metabolism, liver function, renal function, heart, cardiovascular, respiratory and endocrine systems.
(5) Subjects who regularly take medicines or health foods that are said to have moisturizing and whitening effects.
(6) Subjects with symptoms of atopic dermatitis.
(7) Subjects with significant abnormal skin condition at the test site, or subjects with sunburn.
(8) Subjects with severe hay fever symptoms.
(9) Subjects who continuously use or take anti-inflammatory drugs at least once a month.
(10) Subjects who are using or taking drugs such as oral or liniment because of rough skin.
(11) Subjects with food allergies to olive-containing foods.
(12) Night shift worker or day and night shift workers.
(13) Subjects with a digestive organ disease or surgical history that has an influence on digestive absorption.
(14) Subjects who are judged to be inappropriate as subjects from the answers to the subject background questionnaire.
(15) Subjects who are pregnant or breast-feeding, or have the will of pregnancy during the study period.
(16) Subjects who has a medical history or current medical history of drug dependence or alcohol dependence.
(17) Subjects who have participated in similar UV irradiation studies within the last two years.
(18) Subjects who participate in other human studies within the last 4 weeks or who plan to participate in other human studied during the period of this study.
(19) Subjects who are judged as unsuitable for the study by the investigator for the other reasons.

Target sample size

28


Research contact person

Name of lead principal investigator

1st name Kayoko
Middle name
Last name Numano

Organization

NUMANO CLINIC

Division name

Dermatology

Zip code

150-0013

Address

1-11-2 Ebisu, Shibuya-ku, Tokyo

TEL

03-5793-8712

Email

kaco121@yahoo.co.jp


Public contact

Name of contact person

1st name Yoshika
Middle name
Last name Komori

Organization

KSO Corporation

Division name

Sales Department

Zip code

105-0023

Address

7F Shibaura Omodaka Bld., 1-9-7 Shibaura, Minato-ku, Tokyo, Japan

TEL

03-3452-7733

Homepage URL


Email

eigyou27@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

MITSUBISHI-CHEMICAL FOODS CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

General Incorporated Association Clinical Research Review Centers

Address

2972-8-603 Ishikawacho, Hachiouji-shi, Tokyo

Tel

090-3547-6398

Email

crrctakashima@kpd.biglobe.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

28

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 12 Month 02 Day

Date of IRB

2019 Year 12 Month 11 Day

Anticipated trial start date

2020 Year 01 Month 10 Day

Last follow-up date

2020 Year 03 Month 29 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 01 Month 08 Day

Last modified on

2020 Year 06 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044575


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name